Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
10.25
-0.17 (-1.63%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Solid Biosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -207.1 | -174.33 | -124.7 | -96.02 | -85.98 | -72.19 |
Depreciation & Amortization | 1.63 | 1.64 | 2.46 | 2.58 | 2.41 | 2.96 |
Loss (Gain) From Sale of Assets | - | - | - | - | - | 0.09 |
Asset Writedown & Restructuring Costs | - | - | 3.4 | - | - | - |
Loss (Gain) From Sale of Investments | -3.06 | -1.87 | -3.59 | -2.41 | 0.23 | 1.12 |
Stock-Based Compensation | 21.2 | 16.91 | 10.52 | 7.63 | 7.54 | 13.37 |
Other Operating Activities | 8.2 | 8.18 | 9.05 | 2.91 | -18.49 | -0.08 |
Change in Accounts Receivable | - | - | - | - | 0.11 | -0.11 |
Change in Accounts Payable | -0.42 | -1.09 | 2.21 | -0.76 | -5.25 | 1.21 |
Change in Unearned Revenue | - | - | - | - | -8.08 | -12.64 |
Change in Other Net Operating Assets | -7.29 | -5.73 | 0.65 | -8.1 | 9.53 | -11.5 |
Operating Cash Flow | -186.84 | -156.29 | -100.01 | -94.18 | -97.98 | -77.76 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -0.97 | -1.15 | -0.65 | -1.52 | -3.02 | -1.28 |
Sale of Property, Plant & Equipment | 0.09 | 0.09 | 0.01 | - | 0.6 | - |
Cash Acquisitions | - | - | - | - | 31.52 | - |
Investment in Securities | -86.13 | -57.39 | -15.44 | 11.2 | 30.05 | -89.81 |
Investing Cash Flow | -87.09 | -58.45 | -16.09 | 9.69 | 59.16 | -91.09 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | - | - | - | - | 2.14 | - |
Long-Term Debt Repaid | - | -0.72 | -0.47 | - | -0.07 | - |
Net Debt Issued (Repaid) | -0.45 | -0.72 | -0.47 | - | 2.08 | - |
Issuance of Common Stock | 307.91 | 196.85 | 128.02 | 3.12 | 72.75 | 134.99 |
Other Financing Activities | -13.64 | -1.68 | -5.11 | - | - | - |
Financing Cash Flow | 293.82 | 194.45 | 122.44 | 3.12 | 74.83 | 134.99 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash Flow | 19.88 | -20.3 | 6.34 | -81.37 | 36.01 | -33.87 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -187.81 | -157.44 | -100.67 | -95.7 | -100.99 | -79.05 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | - | - | - | - | -1247.74% | -580.36% |
Free Cash Flow Per Share | -1.70 | -1.80 | -2.47 | -4.81 | -11.87 | -11.11 |
Levered Free Cash Flow | -118.24 | -99.7 | -56.21 | -64.71 | -45.32 | -40.95 |
Unlevered Free Cash Flow | -118.24 | -99.7 | -56 | -64.43 | -45.32 | -40.95 |